Breaking: Dentsply Sirona (NASDAQ:XRAY) “Buy” Rating Reiterated by Analysts at Jefferies Today; The Price Objective is Set to $46

August 9, 2018 - By Vernon Prom

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Logo

Investors sentiment increased to 0.5 in Q1 2018. Its up 0.30, from 0.2 in 2017Q4. It increased, as 1 investors sold DENTSPLY SIRONA Inc. shares while 3 reduced holdings. 0 funds opened positions while 2 raised stakes. 569,543 shares or 38.02% more from 412,640 shares in 2017Q4 were reported.

Gemmer Asset Mgmt Lc has 241 shares. West Oak Cap Lc reported 0% stake. Cibc World Corp reported 242,573 shares or 0.13% of all its holdings. Tirschwell & Loewy Incorporated reported 250,918 shares stake. Cardinal Mgmt reported 69,521 shares stake.

Since May 9, 2018, it had 2 insider purchases, and 3 sales for $2.89 million activity. 6,038 shares were sold by COLEMAN MICHAEL J, worth $265,503 on Friday, June 1. The insider ALFANO MICHAEL C sold 1,404 shares worth $64,341. $2.24 million worth of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) was bought by ALEXOS NICHOLAS W.

Dentsply Sirona (NASDAQ:XRAY) Rating Reaffirmed

In an analyst report revealed this morning, Jefferies reaffirmed their “Buy” rating on Dentsply Sirona (NASDAQ:XRAY) shares. The target would suggest a possible upside of 13.90 % from firm’s previous stock close.

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Ratings Coverage

Among 11 analysts covering Dentsply Sirona (NASDAQ:XRAY), 4 have Buy rating, 0 Sell and 7 Hold. Therefore 36% are positive. Dentsply Sirona has $70 highest and $38 lowest target. $53’s average target is 31.24% above currents $40.385 stock price. Dentsply Sirona had 20 analyst reports since March 2, 2018 according to SRatingsIntel. On Wednesday, August 8 the stock rating was downgraded by Stephens to “Equal-Weight”. H.C. Wainwright maintained it with “Hold” rating and $5200 target in Tuesday, May 8 report. The stock has “Buy” rating by Stifel Nicolaus on Tuesday, May 8. The stock of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) has “Neutral” rating given on Tuesday, June 5 by Northcoast. The rating was maintained by H.C. Wainwright with “Hold” on Tuesday, March 27. As per Monday, April 16, the company rating was maintained by Jefferies. On Thursday, June 14 the stock rating was maintained by Morgan Stanley with “Overweight”. Credit Suisse maintained it with “Outperform” rating and $69 target in Friday, March 2 report. The stock has “Overweight” rating by JP Morgan on Monday, March 5. On Wednesday, August 8 the stock rating was maintained by Jefferies with “Buy”.

The stock increased 2.49% or $0.98 during the last trading session, reaching $40.385. About 5.14 million shares traded or 81.39% up from the average. DENTSPLY SIRONA Inc. (NASDAQ:XRAY) has declined 26.16% since August 9, 2017 and is downtrending. It has underperformed by 38.73% the S&P500.

DENTSPLY SIRONA Inc. designs, develops, makes, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company has market cap of $8.98 billion. It operates through two divisions, Dental and Healthcare Consumables; and Technologies. It currently has negative earnings. The firm provides dental consumable products, including endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprising dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

More notable recent DENTSPLY SIRONA Inc. (NASDAQ:XRAY) news were published by: Globenewswire.com which released: “INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of Commencement of an Investigation Involving Possible …” on August 08, 2018, also 247Wallst.com with their article: “Top Analyst Upgrades and Downgrades: AECOM, CyberArk, Dillard’s, Hasbro, Mattel, Newell, Papa John’s, Shopify …” published on August 08, 2018, Benzinga.com published: “The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos’ Maiden Earnings, Paratek Awaits Adcom Verdict” on August 08, 2018. More interesting news about DENTSPLY SIRONA Inc. (NASDAQ:XRAY) were released by: Seekingalpha.com and their article: “Premarket analyst action – healthcare” published on August 07, 2018 as well as Benzinga.com‘s news article titled: “77 Biggest Movers From Yesterday” with publication date: August 08, 2018.

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.